高迁移率族蛋白 B1（HMGB1）的过表达与胶质瘤的预后无关。
Overexpression of high mobility group box 1 (HMGB1) has no correlation with the prognosis in glioma.
机构信息
Department of Medical Genetics & Cell Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province, PR China.
Henan Eye Institute, Henan Provincial People's Hospital, Zhengzhou, Henan Province, PR China.
出版信息
Biomark Med. 2019 Jul;13(10):851-863. doi: 10.2217/bmm-2019-0031. Epub 2019 Jun 26.
We aimed to characterize the role of HMGB1 overexpression in glioma and to evaluate its use as a biomarker. We used the gene expression datasets and tissue microarray to assess the expression levels of HMGB1 among gliomas of all grades; We then assessed its correlation with the malignancy and outcome of glioma. The increase in HMGB1 mRNA and protein levels was found in glioma, but there was no correlation between HMGB1 expression and glioma malignancy, and overall survival and vital status of glioma patients. Overexpression of HMGB1 is not associated with the malignancy and outcome in glioma. And it is not the valuable biomarker for the early diagnosis of glioma.
我们旨在研究 HMGB1 过表达在神经胶质瘤中的作用，并评估其作为生物标志物的用途。我们使用基因表达数据集和组织微阵列评估了所有级别神经胶质瘤中 HMGB1 的表达水平；然后评估了其与神经胶质瘤恶性程度和预后的相关性。发现 HMGB1 mRNA 和蛋白水平在神经胶质瘤中增加，但 HMGB1 表达与神经胶质瘤恶性程度以及神经胶质瘤患者的总生存率和生存状态之间没有相关性。HMGB1 的过表达与神经胶质瘤的恶性程度和预后无关。并且它不是神经胶质瘤早期诊断的有价值的生物标志物。
Zotero 插件